Distinctive Roles for Small Molecule Inhibitors of Immune Checkpoint Proteins (LE072)

SMARCA2/4 degraders relieve the differentiation block in AML via changes in chromatin looping and accessibility

Paralogue selective p300 degraders induce synthetic lethality in pre-clinical models of CBP-deficient and p300-dependent malignancies

Identification and characterization of paralogue selective CBP degraders for potential use in cancer therapy

Development of novel anti-SIRPα/β dual antibody with single-agent phagocytosis activity

A novel CCR4 antagonist induces potent anti-tumor response through inhibition of Treg migration into the tumor microenvironment

Targeting the SWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies

Targeting CBM, A Tri Protein Signalling Hub, By Inhibition Of MALT1 For The Treatment Of B- Cell Lymphomas

A Highly Differentiated Small Molecule Immune Checkpoint Inhibitor Dually Targeting PD-L1 And A2AR For Cancer Therapy